Yahoo
NYSEArca - Delayed Quote USD

iShares Expanded Tech Sector ETF (IGM)

144.96 +1.98 (+1.38%)
At close: May 1 at 4:00:00 PM EDT
145.47 +0.51 (+0.35%)
After hours: May 1 at 7:58:23 PM EDT
Trade IGM on Coinbase
Chart Range Bar
Loading chart for IGM
  • Previous Close 142.98
  • Open 143.48
  • Bid 144.74 x 40000
  • Ask 146.16 x 80000
  • Day's Range 143.35 - 145.21
  • 52 Week Range 93.79 - 145.22
  • Volume 665,089
  • Avg. Volume 836,629
  • Net Assets 7.75B
  • NAV 144.94
  • PE Ratio (TTM) 38.38
  • Yield 0.18%
  • YTD Daily Total Return 12.27%
  • Beta (5Y Monthly) 1.21
  • Expense Ratio (net) 0.39%

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. A significant portion of the underlying index is represented by securities of companies in the technology industry or sector. It is non-diversified.

iShares

Fund Family

Technology

Fund Category

7.75B

Net Assets

2001-03-13

Inception Date

Performance Overview: IGM

View More

Trailing returns as of 5/1/2026. Category is Technology.

YTD Return

IGM
12.27%
Category
5.12%

1-Year Return

IGM
54.17%
Category
30.97%

3-Year Return

IGM
37.44%
Category
19.40%

People Also Watch

Holdings: IGM

View More

Top 10 Holdings (53.53% of Total Assets)

Symbol Company % Assets
Apple Inc. 8.76%
NVIDIA Corporation 8.44%
Microsoft Corporation 8.23%
Broadcom Inc. 8.16%
Alphabet Inc. 4.65%
Meta Platforms, Inc. 4.17%
Alphabet Inc. 3.73%
Netflix, Inc. 2.68%
Micron Technology, Inc. 2.51%
Palantir Technologies Inc. 2.20%

Sector Weightings

Research Reports: IGM

View More
  • Biogen Earnings: Strong First Quarter, Eventful Year Ahead

    Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

    Rating
    Price Target
  • Biogen Earnings: Eventful Year Ahead Despite Expected Decline in Revenue

    Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

    Rating
    Price Target
  • AI driving growth, raising target price to $450

    Taiwan Semiconductor Manufacturing Company Ltd., headquartered in Hsinchu, Taiwan, was founded in 1987 and pioneered the pure-play foundry or 'merchant fab' model. The company serves both integrated semiconductor producers who outsource a portion of their production as well as 'fabless' semiconductor producers who outsource all manufacturing. Taiwan Semi serves over 500 semiconductor customers, producing more than 11,500 distinct products while providing a broad range of advanced, specialty, and advanced packaging technologies.

    Rating
    Price Target
  • ASML Earnings: Outlook Is Magnificent, but Valuation Overshoots Our Fair Value Estimate

    ASML is the leader in lithography systems for manufacturing semiconductors with 90% market share. Lithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. Lithography allows chipmakers to increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s largest clients are TSMC, Samsung, Intel, SK Hynix, and Micron.

    Rating
    Price Target

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: